{"gene":"ARID4A","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2006,"finding":"RBBP1/ARID4A interacts physically with RBBP1L1/ARID4B and with the Snrpn promoter, placing both proteins in a protein complex that regulates genomic imprinting at the PWS/AS domain. Combined homozygous deficiency of Rbbp1/Arid4a and heterozygous deficiency of Rbbp1l1/Arid4b reduced trimethylation of histone H4K20 and H3K9 and reduced DNA methylation at the PWS-IC, shifting the maternal allele toward a paternal epigenotype. Mutations of Rbbp1/Arid4a, Rbbp1l1/Arid4b, or Rb suppressed an Angelman syndrome imprinting defect caused by an AS-IC mutation (genetic epistasis).","method":"Gene-trap mutagenesis, mouse knockout/knockin, ChIP-based epigenetic analysis (histone methylation, DNA methylation), genetic epistasis with Rb and AS-IC mutations","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (genetic epistasis, KO mouse, ChIP-based histone and DNA methylation assays, promoter interaction) in a single rigorous study with clear functional readouts","pmids":["17043311"],"is_preprint":false},{"year":2008,"finding":"Arid4a-deficient mice display increased trimethylation of H3K4, H3K9, and H4K20 in bone marrow, and decreased expression of Hox genes (Hoxb3, Hoxb5, Hoxb6, Hoxb8) and FoxP3, establishing ARID4A as a chromatin remodeling protein that suppresses histone trimethylation and maintains normal hematopoietic gene expression. Loss of Arid4a leads to myelodysplastic/myeloproliferative disorder progressing to AML.","method":"Mouse knockout (Arid4a−/−, Arid4a−/−Arid4b+/−), western blotting, immunofluorescence for histone modifications, RT-PCR for downstream gene expression, flow cytometry, histology","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean KO mouse model with multiple orthogonal readouts (histone modification, gene expression, hematopoietic phenotype), single lab","pmids":["18728284"],"is_preprint":false},{"year":2013,"finding":"ARID4A and ARID4B physically interact with each other. In Sertoli cells, combined deficiency (Arid4a−/−Arid4b+/−) causes spermatogenic arrest and impaired blood-testis barrier, phenocopying Sertoli cell-specific AR and RB knockouts. Molecular analysis identified AR- and RB-responsive genes as downstream targets, indicating ARID4A functions as a transcriptional coactivator for both the androgen receptor (AR) and retinoblastoma protein (RB) pathways.","method":"Mouse knockout genetics, genetic epistasis with AR-KO and RB-KO Sertoli cell models, RT-PCR for AR/RB target genes, histology, blood-testis barrier permeability assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mouse with epistasis to AR and RB pathways, multiple orthogonal methods (genetics, gene expression, barrier assay), single lab","pmids":["23487765"],"is_preprint":false},{"year":2006,"finding":"RBBP1 (ARID4A) is transcriptionally regulated by estrogen receptors ERα and ERβ in an isoform-specific manner: ERα drives sustained induction via an Sp1 site in intron 1, while ERβ induction is transient and requires both the Sp1 and estrogen response elements. ChIP showed ERα binding to the intron 1 enhancer is constitutive whereas ERβ binding is transient. RBBP1 induction by both ER isoforms is SRC2-dependent. Deletion of ERα AF1 converted its induction profile to resemble ERβ.","method":"Microarray, RT-PCR, chromatin immunoprecipitation (ChIP), transient transfection with ER mutants, stable transfection with AF1 deletion, SRC2 overexpression","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and functional transfection with receptor mutants, multiple orthogonal methods, single lab","pmids":["16873370"],"is_preprint":false},{"year":2021,"finding":"The solution structure of the tandem PWWP-ARID domain of RBBP1 (ARID4A) was determined by NMR. The ARID domain interacts with DNA without GC- or AT-rich sequence preference. A long flexible acidic loop L12 within the ARID domain acts as a DNA mimic, binding to the ARID DNA-binding region and inhibiting DNA binding; L12 also binds weakly to the Tudor and chromobarrel domains and more strongly to the histone H2A-H2B heterodimer. Both L12 and DNA enhance chromobarrel binding to H3K4me3 and H4K20me3.","method":"NMR structure determination, NMR titration, deletion mutagenesis of loop L12","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR solution structure with functional NMR titration and mutagenesis, multiple orthogonal structural and binding analyses in one study","pmids":["34506790"],"is_preprint":false},{"year":2022,"finding":"The crystal structure of the PWWP-ARID tandem supramodule of ARID4A was determined at 2.05 Å, revealing that PWWP and ARID form a structural and functional supramodule. A disease-associated missense variant p.His411Asp (in the ARID domain) causes a less compact conformation and reduces dsDNA-binding ability. The mutation also decreases G0/G1 arrest and promotes cell proliferation in HEK293T cells.","method":"X-ray crystallography (2.05 Å), dsDNA-binding assays with wild-type and mutant protein, cell cycle analysis by flow cytometry, cell proliferation assay","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure combined with binding assays and functional cell cycle measurements in a single study","pmids":["35365808"],"is_preprint":false},{"year":2018,"finding":"The crystal structure of the chromo barrel domain of RBBP1 (ARID4A) was determined. ITC assays showed that DNA does not significantly enhance histone H4K20me3 binding by the isolated chromo barrel domain, and surface charge analysis indicated the chromo barrel lacks a typical DNA-binding surface, suggesting this domain alone does not bind DNA. (Negative result: DNA-enhanced H4K20me3 binding requires additional domains beyond the isolated chromo barrel.)","method":"X-ray crystallography, isothermal titration calorimetry (ITC), surface charge analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structure plus ITC, but single lab and the main finding is a negative result (DNA does not enhance binding in isolated domain)","pmids":["29408527"],"is_preprint":false},{"year":2025,"finding":"ARID4A functions as an RNA-binding protein (RBP) that stabilizes mRNAs of metastasis-suppressing genes (MTSS1, TIMP2, Rb1, PTEN) by binding a conserved structural RNA element in their 3'UTRs. The ARID domain of ARID4A is required for mRNA stabilization and metastasis inhibition. Loss of ARID4A promotes breast tumor cell migration and invasion in vitro and in vivo.","method":"RNA immunoprecipitation (RIP), RIP-ChIP, mRNA stability assay, EMSA, luciferase assay, gain-of-function and loss-of-function experiments in vitro and in vivo (mouse xenograft or orthotopic model implied), PCR array","journal":"Cancer medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP and EMSA directly demonstrate RNA binding; mRNA stability and functional KD/OE with defined phenotypic readout; single lab","pmids":["40066676"],"is_preprint":false},{"year":2018,"finding":"Both ARID4A and ARID4B are direct targets of miR-30d; miR-30d negatively regulates their mRNA levels. Knockout of ARID4A and/or ARID4B promotes prostate cancer cell proliferation, migration, and invasion in vitro.","method":"Luciferase reporter assay for miR-30d targeting of 3'UTR, qRT-PCR, siRNA/CRISPR knockout, proliferation/migration/invasion assays","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — luciferase 3'UTR assay confirms miR-30d targeting; KO functional assays; single lab","pmids":["29797600"],"is_preprint":false},{"year":2025,"finding":"HERC2 binds to ARID4A via a conserved 'DxDKDxD' motif in ARID4A that is recognized by the RLD2 domain of HERC2, placing ARID4A as a binding partner in the HERC2 interaction network relevant to brain development.","method":"Quantitative binding assays, X-ray crystallography of HERC2 RLD2 domain complexes, sequence conservation analysis","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 2 / Weak — structural and binding data are for the HERC2/DOCK10 complex as the primary focus; ARID4A is listed as one of several HERC2 interactors without dedicated functional follow-up; preprint, not peer-reviewed","pmids":["bio_10.1101_2025.09.16.670041"],"is_preprint":true}],"current_model":"ARID4A (RBBP1) is a multidomain chromatin- and RNA-binding protein that: (1) forms a complex with ARID4B and binds the Snrpn promoter to regulate imprinting at the PWS/AS domain by controlling H3K9me3, H4K20me3, and DNA methylation; (2) acts as a transcriptional coactivator for the retinoblastoma protein (RB) and androgen receptor (AR) pathways, with its loss causing aberrant histone hypermethylation and leukemia or spermatogenic failure in mice; (3) uses a PWWP-ARID supramodule (structurally determined by X-ray crystallography and NMR) to bind dsDNA non-sequence-specifically, with an intramolecular acidic loop L12 acting as a DNA mimic to modulate chromatin engagement; and (4) functions as an RNA-binding protein that stabilizes 3'UTR elements of metastasis-suppressor mRNAs (MTSS1, TIMP2, Rb1, PTEN) to inhibit breast cancer metastasis."},"narrative":{"mechanistic_narrative":"ARID4A (RBBP1) is a multidomain chromatin-associated protein that suppresses aberrant histone trimethylation and acts as a transcriptional coregulator within epigenetic and nuclear-receptor pathways [PMID:17043311, PMID:18728284]. In complex with its paralog ARID4B, it binds the Snrpn promoter to maintain genomic imprinting at the Prader-Willi/Angelman domain, controlling H3K9me3, H4K20me3, and DNA methylation at the imprinting center [PMID:17043311]. Loss of ARID4A elevates trimethylation of H3K4, H3K9, and H4K20 and deregulates hematopoietic gene expression, driving a myelodysplastic/myeloproliferative disorder that progresses to AML in mice [PMID:18728284], while combined ARID4A/ARID4B deficiency in Sertoli cells causes spermatogenic arrest by phenocopying loss of the androgen receptor and retinoblastoma protein pathways for which ARID4A serves as a transcriptional coactivator [PMID:23487765]. Structurally, ARID4A engages chromatin through a PWWP-ARID supramodule whose ARID domain binds dsDNA without sequence preference, while an intramolecular acidic loop L12 acts as a DNA mimic that autoinhibits DNA binding and modulates histone-mark engagement by the chromobarrel domain [PMID:34506790, PMID:35365808]; a disease-associated p.His411Asp variant loosens this module, weakens dsDNA binding, and promotes proliferation [PMID:35365808]. Beyond chromatin, ARID4A functions as an RNA-binding protein whose ARID domain recognizes a conserved 3'UTR structural element to stabilize metastasis-suppressor mRNAs including MTSS1, TIMP2, Rb1, and PTEN, thereby restraining breast cancer cell migration and invasion [PMID:40066676].","teleology":[{"year":2006,"claim":"Established ARID4A as a functional partner of ARID4B in an imprinting-regulatory complex, answering how the PWS/AS locus maintains parent-of-origin epigenetic state.","evidence":"Gene-trap KO/knockin mice, ChIP-based histone and DNA methylation assays, and genetic epistasis with Rb and AS-IC mutations","pmids":["17043311"],"confidence":"High","gaps":["Does not define which domain of ARID4A docks at the Snrpn promoter","Mechanism linking the ARID4A/ARID4B complex to the histone and DNA methyltransferases that deposit the marks is unresolved"]},{"year":2006,"claim":"Showed ARID4A is itself an estrogen-responsive gene under isoform-specific ERα/ERβ control, placing it downstream of nuclear-receptor signaling.","evidence":"Microarray, ChIP, and transfection with ER and AF1-deletion mutants plus SRC2 overexpression","pmids":["16873370"],"confidence":"Medium","gaps":["Does not connect estrogen induction of ARID4A to a specific chromatin or imprinting output","Physiological context of ER-driven ARID4A induction untested in vivo"]},{"year":2008,"claim":"Demonstrated that ARID4A loss elevates histone trimethylation and deregulates hematopoietic gene expression, defining a tumor-suppressive chromatin-remodeling role linked to leukemogenesis.","evidence":"Arid4a-deficient mice with western blot/IF for histone marks, RT-PCR for Hox and FoxP3 genes, and hematopoietic phenotyping","pmids":["18728284"],"confidence":"High","gaps":["Does not establish whether ARID4A directly recruits or antagonizes a specific methyltransferase","Direct versus indirect basis of Hox/FoxP3 deregulation not separated"]},{"year":2013,"claim":"Defined ARID4A as a transcriptional coactivator for both AR and RB pathways, explaining its requirement for Sertoli-cell function and blood-testis barrier integrity.","evidence":"Sertoli-cell-specific KO genetics with epistasis to AR-KO and RB-KO models, RT-PCR for target genes, and barrier permeability assays","pmids":["23487765"],"confidence":"High","gaps":["Does not show direct physical contact of ARID4A with AR or RB on target promoters","Tissue specificity of the AR/RB coactivator role outside Sertoli cells untested"]},{"year":2018,"claim":"Resolved the isolated chromobarrel domain structure and showed it alone lacks a DNA-binding surface, indicating histone-mark reading requires additional domains.","evidence":"X-ray crystallography, ITC, and surface-charge analysis of the isolated chromobarrel","pmids":["29408527"],"confidence":"Medium","gaps":["Negative result confined to the isolated domain","Does not test the chromobarrel in the context of the full PWWP-ARID module"]},{"year":2018,"claim":"Identified ARID4A (and ARID4B) as direct miR-30d targets whose loss enhances prostate cancer cell aggressiveness, framing ARID4A as a post-transcriptionally controlled tumor suppressor.","evidence":"Luciferase 3'UTR reporter, qRT-PCR, and knockout proliferation/migration/invasion assays","pmids":["29797600"],"confidence":"Medium","gaps":["Does not define the molecular pathway by which ARID4A loss drives invasion","In vivo relevance of miR-30d/ARID4A axis not tested"]},{"year":2021,"claim":"Provided the mechanistic basis for chromatin engagement, showing the ARID domain binds dsDNA non-specifically and is autoinhibited by an intramolecular acidic loop L12 acting as a DNA mimic.","evidence":"NMR solution structure of the tandem PWWP-ARID domain with NMR titration and L12 deletion mutagenesis","pmids":["34506790"],"confidence":"High","gaps":["Does not establish how L12 autoinhibition is relieved in vivo","Functional consequence of L12-H2A-H2B binding for nucleosome targeting unclear"]},{"year":2022,"claim":"Defined PWWP and ARID as a single structural/functional supramodule and connected a disease-associated p.His411Asp variant to weakened dsDNA binding and loss of cell-cycle control.","evidence":"2.05 Å crystal structure with dsDNA-binding assays and flow-cytometry cell-cycle/proliferation readouts in HEK293T cells","pmids":["35365808"],"confidence":"High","gaps":["Does not link the variant to a defined human disease through family or rescue genetics","Chromatin-level consequence of weakened DNA binding not measured"]},{"year":2025,"claim":"Uncovered a non-chromatin function: ARID4A is an RNA-binding protein that stabilizes metastasis-suppressor mRNAs via a conserved 3'UTR element, repositioning it as a post-transcriptional regulator of breast cancer metastasis.","evidence":"RIP, RIP-ChIP, EMSA, mRNA-stability and luciferase assays, plus gain/loss-of-function in vitro and in vivo","pmids":["40066676"],"confidence":"Medium","gaps":["Does not reconcile how the same ARID domain mediates both DNA and RNA binding","Structural basis of 3'UTR element recognition not determined"]},{"year":2025,"claim":"Placed ARID4A in the HERC2 interaction network via a conserved DxDKDxD motif recognized by the HERC2 RLD2 domain, hinting at a role relevant to brain development.","evidence":"Quantitative binding assays and X-ray crystallography of HERC2 RLD2 complexes (preprint)","pmids":["bio_10.1101_2025.09.16.670041"],"confidence":"Low","gaps":["ARID4A is one of several listed HERC2 interactors without dedicated functional follow-up","Not peer-reviewed; functional consequence of the ARID4A-HERC2 interaction untested"]},{"year":null,"claim":"How ARID4A integrates its chromatin-remodeling, nuclear-receptor coactivator, and mRNA-stabilizing activities into a unified cellular program remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of ARID4A bound to a nucleosome or to its target 3'UTR RNA","Mechanism coupling histone-mark reading to transcriptional or post-transcriptional output unknown","Identity of the methyltransferase activity antagonized by ARID4A not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[4,5]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[7]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[4]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[7]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,5]}],"complexes":["ARID4A-ARID4B chromatin complex"],"partners":["ARID4B","RB1","AR","HERC2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29374","full_name":"AT-rich interactive domain-containing protein 4A","aliases":["Retinoblastoma-binding protein 1","RBBP-1"],"length_aa":1257,"mass_kda":142.8,"function":"DNA-binding protein which modulates activity of several transcription factors including RB1 (retinoblastoma-associated protein) and AR (androgen receptor) (By similarity). May function as part of an mSin3A repressor complex (PubMed:14581478). Has no intrinsic transcriptional activity (By similarity). Plays a role in the regulation of epigenetic modifications at the PWS/AS imprinting center near the SNRPN promoter, where it might function as part of a complex with RB1 and ARID4B (By similarity). Involved in spermatogenesis, together with ARID4B, where it acts as a transcriptional coactivator for AR and enhances expression of genes required for sperm maturation. Regulates expression of the tight junction protein CLDN3 in the testis, which is important for integrity of the blood-testis barrier (By similarity). Plays a role in myeloid homeostasis where it regulates the histone methylation state of bone marrow cells and expression of various genes involved in hematopoiesis. May function as a leukemia suppressor (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P29374/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARID4A","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HDAC1","stoichiometry":0.2},{"gene":"HDAC2","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ARID4A","total_profiled":1310},"omim":[{"mim_id":"618514","title":"BRMS1-LIKE TRANSCRIPTIONAL REPRESSOR; BRMS1L","url":"https://www.omim.org/entry/618514"},{"mim_id":"609696","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 4B; ARID4B","url":"https://www.omim.org/entry/609696"},{"mim_id":"606259","title":"BRMS1 TRANSCRIPTIONAL REPRESSOR AND ANOIKIS REGULATOR; BRMS1","url":"https://www.omim.org/entry/606259"},{"mim_id":"604215","title":"INHIBITOR OF GROWTH 2; ING2","url":"https://www.omim.org/entry/604215"},{"mim_id":"180201","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 4A; ARID4A","url":"https://www.omim.org/entry/180201"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ARID4A"},"hgnc":{"alias_symbol":["RBP1","RBP-1"],"prev_symbol":["RBBP1"]},"alphafold":{"accession":"P29374","domains":[{"cath_id":"2.30.30","chopping":"13-123","consensus_level":"medium","plddt":86.2627,"start":13,"end":123},{"cath_id":"2.30.30.140","chopping":"168-261","consensus_level":"medium","plddt":86.0346,"start":168,"end":261},{"cath_id":"1.10.150.60","chopping":"265-275_308-410","consensus_level":"medium","plddt":89.4449,"start":265,"end":410},{"cath_id":"2.30.30.140","chopping":"577-628","consensus_level":"medium","plddt":93.1069,"start":577,"end":628}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29374","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29374-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29374-F1-predicted_aligned_error_v6.png","plddt_mean":56.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARID4A","jax_strain_url":"https://www.jax.org/strain/search?query=ARID4A"},"sequence":{"accession":"P29374","fasta_url":"https://rest.uniprot.org/uniprotkb/P29374.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29374/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29374"}},"corpus_meta":[{"pmid":"19714238","id":"PMC_19714238","title":"The cyst nematode SPRYSEC protein RBP-1 elicits Gpa2- and RanGAP2-dependent plant cell death.","date":"2009","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/19714238","citation_count":125,"is_preprint":false},{"pmid":"24382590","id":"PMC_24382590","title":"Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24382590","citation_count":101,"is_preprint":false},{"pmid":"17043311","id":"PMC_17043311","title":"Deficiency of Rbbp1/Arid4a and Rbbp1l1/Arid4b alters epigenetic modifications and suppresses an imprinting defect in the PWS/AS domain.","date":"2006","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17043311","citation_count":83,"is_preprint":false},{"pmid":"18728284","id":"PMC_18728284","title":"Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes.","date":"2008","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/18728284","citation_count":75,"is_preprint":false},{"pmid":"23487765","id":"PMC_23487765","title":"ARID4A and ARID4B regulate male fertility, a functional link to the AR and RB pathways.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23487765","citation_count":60,"is_preprint":false},{"pmid":"12535708","id":"PMC_12535708","title":"Identification and polymorphism of Plasmodium vivax RBP-1 peptides which bind specifically to reticulocytes.","date":"2002","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/12535708","citation_count":28,"is_preprint":false},{"pmid":"16873370","id":"PMC_16873370","title":"Estrogen receptor isoform-specific regulation of the retinoblastoma-binding protein 1 (RBBP1) gene: roles of AF1 and enhancer elements.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16873370","citation_count":19,"is_preprint":false},{"pmid":"29797600","id":"PMC_29797600","title":"Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29797600","citation_count":18,"is_preprint":false},{"pmid":"22192092","id":"PMC_22192092","title":"The evolution of the Gp-Rbp-1 gene in Globodera pallida includes multiple selective replacements.","date":"2011","source":"Molecular plant pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22192092","citation_count":16,"is_preprint":false},{"pmid":"23601377","id":"PMC_23601377","title":"Evolution and variability of Solanum RanGAP2, a cofactor in the incompatible interaction between the resistance protein GPA2 and the Globodera pallida effector Gp-RBP-1.","date":"2013","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/23601377","citation_count":8,"is_preprint":false},{"pmid":"30195942","id":"PMC_30195942","title":"Functional haplotypes of ARID4A affect promoter activity and semen quality of bulls.","date":"2018","source":"Animal reproduction science","url":"https://pubmed.ncbi.nlm.nih.gov/30195942","citation_count":7,"is_preprint":false},{"pmid":"34506790","id":"PMC_34506790","title":"Structural Insight into Chromatin Recognition by Multiple Domains of the Tumor Suppressor RBBP1.","date":"2021","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34506790","citation_count":6,"is_preprint":false},{"pmid":"10496363","id":"PMC_10496363","title":"Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10496363","citation_count":6,"is_preprint":false},{"pmid":"35365808","id":"PMC_35365808","title":"A novel heterozygous missense variant of the ARID4A gene identified in Han Chinese families with schizophrenia-diagnosed siblings that interferes with DNA-binding activity.","date":"2022","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/35365808","citation_count":4,"is_preprint":false},{"pmid":"29408527","id":"PMC_29408527","title":"Crystal structure of chromo barrel domain of RBBP1.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29408527","citation_count":4,"is_preprint":false},{"pmid":"30666492","id":"PMC_30666492","title":"Resonance assignments for the tandem PWWP-ARID domains of human RBBP1.","date":"2019","source":"Biomolecular NMR assignments","url":"https://pubmed.ncbi.nlm.nih.gov/30666492","citation_count":2,"is_preprint":false},{"pmid":"40066676","id":"PMC_40066676","title":"Arid4a Suppresses Breast Tumor Metastasis by Enhancing MTSS1 Expression via mRNA Stability.","date":"2025","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40066676","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.16.670041","title":"Structural analysis of HERC2/UBE3A and HERC2/DOCK10 complexes provides new insights into the molecular basis of Angelman, Angelman-like and Dup15q Syndromes","date":"2025-09-16","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.16.670041","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12533,"output_tokens":3189,"usd":0.042717,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10583,"output_tokens":3732,"usd":0.073108,"stage2_stop_reason":"end_turn"},"total_usd":0.115825,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"RBBP1/ARID4A interacts physically with RBBP1L1/ARID4B and with the Snrpn promoter, placing both proteins in a protein complex that regulates genomic imprinting at the PWS/AS domain. Combined homozygous deficiency of Rbbp1/Arid4a and heterozygous deficiency of Rbbp1l1/Arid4b reduced trimethylation of histone H4K20 and H3K9 and reduced DNA methylation at the PWS-IC, shifting the maternal allele toward a paternal epigenotype. Mutations of Rbbp1/Arid4a, Rbbp1l1/Arid4b, or Rb suppressed an Angelman syndrome imprinting defect caused by an AS-IC mutation (genetic epistasis).\",\n      \"method\": \"Gene-trap mutagenesis, mouse knockout/knockin, ChIP-based epigenetic analysis (histone methylation, DNA methylation), genetic epistasis with Rb and AS-IC mutations\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (genetic epistasis, KO mouse, ChIP-based histone and DNA methylation assays, promoter interaction) in a single rigorous study with clear functional readouts\",\n      \"pmids\": [\"17043311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Arid4a-deficient mice display increased trimethylation of H3K4, H3K9, and H4K20 in bone marrow, and decreased expression of Hox genes (Hoxb3, Hoxb5, Hoxb6, Hoxb8) and FoxP3, establishing ARID4A as a chromatin remodeling protein that suppresses histone trimethylation and maintains normal hematopoietic gene expression. Loss of Arid4a leads to myelodysplastic/myeloproliferative disorder progressing to AML.\",\n      \"method\": \"Mouse knockout (Arid4a−/−, Arid4a−/−Arid4b+/−), western blotting, immunofluorescence for histone modifications, RT-PCR for downstream gene expression, flow cytometry, histology\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KO mouse model with multiple orthogonal readouts (histone modification, gene expression, hematopoietic phenotype), single lab\",\n      \"pmids\": [\"18728284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ARID4A and ARID4B physically interact with each other. In Sertoli cells, combined deficiency (Arid4a−/−Arid4b+/−) causes spermatogenic arrest and impaired blood-testis barrier, phenocopying Sertoli cell-specific AR and RB knockouts. Molecular analysis identified AR- and RB-responsive genes as downstream targets, indicating ARID4A functions as a transcriptional coactivator for both the androgen receptor (AR) and retinoblastoma protein (RB) pathways.\",\n      \"method\": \"Mouse knockout genetics, genetic epistasis with AR-KO and RB-KO Sertoli cell models, RT-PCR for AR/RB target genes, histology, blood-testis barrier permeability assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with epistasis to AR and RB pathways, multiple orthogonal methods (genetics, gene expression, barrier assay), single lab\",\n      \"pmids\": [\"23487765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RBBP1 (ARID4A) is transcriptionally regulated by estrogen receptors ERα and ERβ in an isoform-specific manner: ERα drives sustained induction via an Sp1 site in intron 1, while ERβ induction is transient and requires both the Sp1 and estrogen response elements. ChIP showed ERα binding to the intron 1 enhancer is constitutive whereas ERβ binding is transient. RBBP1 induction by both ER isoforms is SRC2-dependent. Deletion of ERα AF1 converted its induction profile to resemble ERβ.\",\n      \"method\": \"Microarray, RT-PCR, chromatin immunoprecipitation (ChIP), transient transfection with ER mutants, stable transfection with AF1 deletion, SRC2 overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and functional transfection with receptor mutants, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"16873370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The solution structure of the tandem PWWP-ARID domain of RBBP1 (ARID4A) was determined by NMR. The ARID domain interacts with DNA without GC- or AT-rich sequence preference. A long flexible acidic loop L12 within the ARID domain acts as a DNA mimic, binding to the ARID DNA-binding region and inhibiting DNA binding; L12 also binds weakly to the Tudor and chromobarrel domains and more strongly to the histone H2A-H2B heterodimer. Both L12 and DNA enhance chromobarrel binding to H3K4me3 and H4K20me3.\",\n      \"method\": \"NMR structure determination, NMR titration, deletion mutagenesis of loop L12\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR solution structure with functional NMR titration and mutagenesis, multiple orthogonal structural and binding analyses in one study\",\n      \"pmids\": [\"34506790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The crystal structure of the PWWP-ARID tandem supramodule of ARID4A was determined at 2.05 Å, revealing that PWWP and ARID form a structural and functional supramodule. A disease-associated missense variant p.His411Asp (in the ARID domain) causes a less compact conformation and reduces dsDNA-binding ability. The mutation also decreases G0/G1 arrest and promotes cell proliferation in HEK293T cells.\",\n      \"method\": \"X-ray crystallography (2.05 Å), dsDNA-binding assays with wild-type and mutant protein, cell cycle analysis by flow cytometry, cell proliferation assay\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure combined with binding assays and functional cell cycle measurements in a single study\",\n      \"pmids\": [\"35365808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The crystal structure of the chromo barrel domain of RBBP1 (ARID4A) was determined. ITC assays showed that DNA does not significantly enhance histone H4K20me3 binding by the isolated chromo barrel domain, and surface charge analysis indicated the chromo barrel lacks a typical DNA-binding surface, suggesting this domain alone does not bind DNA. (Negative result: DNA-enhanced H4K20me3 binding requires additional domains beyond the isolated chromo barrel.)\",\n      \"method\": \"X-ray crystallography, isothermal titration calorimetry (ITC), surface charge analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structure plus ITC, but single lab and the main finding is a negative result (DNA does not enhance binding in isolated domain)\",\n      \"pmids\": [\"29408527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ARID4A functions as an RNA-binding protein (RBP) that stabilizes mRNAs of metastasis-suppressing genes (MTSS1, TIMP2, Rb1, PTEN) by binding a conserved structural RNA element in their 3'UTRs. The ARID domain of ARID4A is required for mRNA stabilization and metastasis inhibition. Loss of ARID4A promotes breast tumor cell migration and invasion in vitro and in vivo.\",\n      \"method\": \"RNA immunoprecipitation (RIP), RIP-ChIP, mRNA stability assay, EMSA, luciferase assay, gain-of-function and loss-of-function experiments in vitro and in vivo (mouse xenograft or orthotopic model implied), PCR array\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP and EMSA directly demonstrate RNA binding; mRNA stability and functional KD/OE with defined phenotypic readout; single lab\",\n      \"pmids\": [\"40066676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Both ARID4A and ARID4B are direct targets of miR-30d; miR-30d negatively regulates their mRNA levels. Knockout of ARID4A and/or ARID4B promotes prostate cancer cell proliferation, migration, and invasion in vitro.\",\n      \"method\": \"Luciferase reporter assay for miR-30d targeting of 3'UTR, qRT-PCR, siRNA/CRISPR knockout, proliferation/migration/invasion assays\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — luciferase 3'UTR assay confirms miR-30d targeting; KO functional assays; single lab\",\n      \"pmids\": [\"29797600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HERC2 binds to ARID4A via a conserved 'DxDKDxD' motif in ARID4A that is recognized by the RLD2 domain of HERC2, placing ARID4A as a binding partner in the HERC2 interaction network relevant to brain development.\",\n      \"method\": \"Quantitative binding assays, X-ray crystallography of HERC2 RLD2 domain complexes, sequence conservation analysis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2 / Weak — structural and binding data are for the HERC2/DOCK10 complex as the primary focus; ARID4A is listed as one of several HERC2 interactors without dedicated functional follow-up; preprint, not peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.09.16.670041\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ARID4A (RBBP1) is a multidomain chromatin- and RNA-binding protein that: (1) forms a complex with ARID4B and binds the Snrpn promoter to regulate imprinting at the PWS/AS domain by controlling H3K9me3, H4K20me3, and DNA methylation; (2) acts as a transcriptional coactivator for the retinoblastoma protein (RB) and androgen receptor (AR) pathways, with its loss causing aberrant histone hypermethylation and leukemia or spermatogenic failure in mice; (3) uses a PWWP-ARID supramodule (structurally determined by X-ray crystallography and NMR) to bind dsDNA non-sequence-specifically, with an intramolecular acidic loop L12 acting as a DNA mimic to modulate chromatin engagement; and (4) functions as an RNA-binding protein that stabilizes 3'UTR elements of metastasis-suppressor mRNAs (MTSS1, TIMP2, Rb1, PTEN) to inhibit breast cancer metastasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARID4A (RBBP1) is a multidomain chromatin-associated protein that suppresses aberrant histone trimethylation and acts as a transcriptional coregulator within epigenetic and nuclear-receptor pathways [#0, #1]. In complex with its paralog ARID4B, it binds the Snrpn promoter to maintain genomic imprinting at the Prader-Willi/Angelman domain, controlling H3K9me3, H4K20me3, and DNA methylation at the imprinting center [#0]. Loss of ARID4A elevates trimethylation of H3K4, H3K9, and H4K20 and deregulates hematopoietic gene expression, driving a myelodysplastic/myeloproliferative disorder that progresses to AML in mice [#1], while combined ARID4A/ARID4B deficiency in Sertoli cells causes spermatogenic arrest by phenocopying loss of the androgen receptor and retinoblastoma protein pathways for which ARID4A serves as a transcriptional coactivator [#2]. Structurally, ARID4A engages chromatin through a PWWP-ARID supramodule whose ARID domain binds dsDNA without sequence preference, while an intramolecular acidic loop L12 acts as a DNA mimic that autoinhibits DNA binding and modulates histone-mark engagement by the chromobarrel domain [#4, #5]; a disease-associated p.His411Asp variant loosens this module, weakens dsDNA binding, and promotes proliferation [#5]. Beyond chromatin, ARID4A functions as an RNA-binding protein whose ARID domain recognizes a conserved 3'UTR structural element to stabilize metastasis-suppressor mRNAs including MTSS1, TIMP2, Rb1, and PTEN, thereby restraining breast cancer cell migration and invasion [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established ARID4A as a functional partner of ARID4B in an imprinting-regulatory complex, answering how the PWS/AS locus maintains parent-of-origin epigenetic state.\",\n      \"evidence\": \"Gene-trap KO/knockin mice, ChIP-based histone and DNA methylation assays, and genetic epistasis with Rb and AS-IC mutations\",\n      \"pmids\": [\"17043311\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not define which domain of ARID4A docks at the Snrpn promoter\", \"Mechanism linking the ARID4A/ARID4B complex to the histone and DNA methyltransferases that deposit the marks is unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed ARID4A is itself an estrogen-responsive gene under isoform-specific ERα/ERβ control, placing it downstream of nuclear-receptor signaling.\",\n      \"evidence\": \"Microarray, ChIP, and transfection with ER and AF1-deletion mutants plus SRC2 overexpression\",\n      \"pmids\": [\"16873370\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not connect estrogen induction of ARID4A to a specific chromatin or imprinting output\", \"Physiological context of ER-driven ARID4A induction untested in vivo\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated that ARID4A loss elevates histone trimethylation and deregulates hematopoietic gene expression, defining a tumor-suppressive chromatin-remodeling role linked to leukemogenesis.\",\n      \"evidence\": \"Arid4a-deficient mice with western blot/IF for histone marks, RT-PCR for Hox and FoxP3 genes, and hematopoietic phenotyping\",\n      \"pmids\": [\"18728284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish whether ARID4A directly recruits or antagonizes a specific methyltransferase\", \"Direct versus indirect basis of Hox/FoxP3 deregulation not separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined ARID4A as a transcriptional coactivator for both AR and RB pathways, explaining its requirement for Sertoli-cell function and blood-testis barrier integrity.\",\n      \"evidence\": \"Sertoli-cell-specific KO genetics with epistasis to AR-KO and RB-KO models, RT-PCR for target genes, and barrier permeability assays\",\n      \"pmids\": [\"23487765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not show direct physical contact of ARID4A with AR or RB on target promoters\", \"Tissue specificity of the AR/RB coactivator role outside Sertoli cells untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved the isolated chromobarrel domain structure and showed it alone lacks a DNA-binding surface, indicating histone-mark reading requires additional domains.\",\n      \"evidence\": \"X-ray crystallography, ITC, and surface-charge analysis of the isolated chromobarrel\",\n      \"pmids\": [\"29408527\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative result confined to the isolated domain\", \"Does not test the chromobarrel in the context of the full PWWP-ARID module\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified ARID4A (and ARID4B) as direct miR-30d targets whose loss enhances prostate cancer cell aggressiveness, framing ARID4A as a post-transcriptionally controlled tumor suppressor.\",\n      \"evidence\": \"Luciferase 3'UTR reporter, qRT-PCR, and knockout proliferation/migration/invasion assays\",\n      \"pmids\": [\"29797600\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not define the molecular pathway by which ARID4A loss drives invasion\", \"In vivo relevance of miR-30d/ARID4A axis not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided the mechanistic basis for chromatin engagement, showing the ARID domain binds dsDNA non-specifically and is autoinhibited by an intramolecular acidic loop L12 acting as a DNA mimic.\",\n      \"evidence\": \"NMR solution structure of the tandem PWWP-ARID domain with NMR titration and L12 deletion mutagenesis\",\n      \"pmids\": [\"34506790\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish how L12 autoinhibition is relieved in vivo\", \"Functional consequence of L12-H2A-H2B binding for nucleosome targeting unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined PWWP and ARID as a single structural/functional supramodule and connected a disease-associated p.His411Asp variant to weakened dsDNA binding and loss of cell-cycle control.\",\n      \"evidence\": \"2.05 Å crystal structure with dsDNA-binding assays and flow-cytometry cell-cycle/proliferation readouts in HEK293T cells\",\n      \"pmids\": [\"35365808\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not link the variant to a defined human disease through family or rescue genetics\", \"Chromatin-level consequence of weakened DNA binding not measured\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Uncovered a non-chromatin function: ARID4A is an RNA-binding protein that stabilizes metastasis-suppressor mRNAs via a conserved 3'UTR element, repositioning it as a post-transcriptional regulator of breast cancer metastasis.\",\n      \"evidence\": \"RIP, RIP-ChIP, EMSA, mRNA-stability and luciferase assays, plus gain/loss-of-function in vitro and in vivo\",\n      \"pmids\": [\"40066676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not reconcile how the same ARID domain mediates both DNA and RNA binding\", \"Structural basis of 3'UTR element recognition not determined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Placed ARID4A in the HERC2 interaction network via a conserved DxDKDxD motif recognized by the HERC2 RLD2 domain, hinting at a role relevant to brain development.\",\n      \"evidence\": \"Quantitative binding assays and X-ray crystallography of HERC2 RLD2 complexes (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.09.16.670041\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"ARID4A is one of several listed HERC2 interactors without dedicated functional follow-up\", \"Not peer-reviewed; functional consequence of the ARID4A-HERC2 interaction untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ARID4A integrates its chromatin-remodeling, nuclear-receptor coactivator, and mRNA-stabilizing activities into a unified cellular program remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of ARID4A bound to a nucleosome or to its target 3'UTR RNA\", \"Mechanism coupling histone-mark reading to transcriptional or post-transcriptional output unknown\", \"Identity of the methyltransferase activity antagonized by ARID4A not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 5]}\n    ],\n    \"complexes\": [\"ARID4A-ARID4B chromatin complex\"],\n    \"partners\": [\"ARID4B\", \"RB1\", \"AR\", \"HERC2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}